VitalConnect, a San Jose, CA-based provider of medical-grade wearable biosensor systems has raised $33 million in Series C funding led by new investors MVM Life Science Partners and Baxter Ventures, the venture arm of Baxter International. The company plans to utilize the funding to commercialize the VitalConnect Platform and make significant strides in changing the way patient monitoring is utilized in hospitals and at home. As part of the latest funding round, Dr. Stephen Reeders, MVM founder, will join the VitalConnect Board of Directors.
“The integration of wearable biosensors into existing and emerging healthcare environments will change the care paradigm within hospitals as well as enable virtual care opportunities that were never before possible,” said Dr. Nersi Nazari, VitalConnect Chairman and CEO. “Biosensors, when paired with sophisticated data analytics platforms, have the unique opportunity to enable better care for patients while reducing costs for hospitals – a win for both patients and providers.”
Founded in 2011, The VitalPatch® wearable biosensor is a lightweight, wireless, adhesive patch that continuously monitors and records eight patient vital signs. The VitalConnect Platform integrates the VitalPatch biosensor with mobile and cloud-based software and analytics so patients can be monitored around the clock and across care settings. Patients enjoy the comfort the VitalPatch provides while caregivers have access to unprecedented insight into a patient’s health, aiding in critical decisions when it matters most. The VitalConnect Platform is already being implemented in hospitals across the United States and select locations globally – results have demonstrated high patient satisfaction and improved economics.
